NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) Sees Large Decline in Short Interest

NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) was the recipient of a significant decline in short interest in the month of February. As of February 28th, there was short interest totalling 89,000 shares, a decline of 19.2% from the February 13th total of 110,200 shares. Currently, 2.1% of the shares of the company are sold short. Based on an average daily volume of 234,600 shares, the days-to-cover ratio is currently 0.4 days.

NovaBay Pharmaceuticals Stock Performance

Shares of NYSEAMERICAN:NBY traded down $0.03 on Wednesday, reaching $0.60. 19,995 shares of the company’s stock were exchanged, compared to its average volume of 917,941. NovaBay Pharmaceuticals has a fifty-two week low of $0.36 and a fifty-two week high of $9.08. The stock has a market capitalization of $2.54 million, a price-to-earnings ratio of -0.06 and a beta of 2.82.

About NovaBay Pharmaceuticals

NovaBay Pharmaceuticals, Inc develops and sells eyecare and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; Avenova Eye Health Support antioxidant-rich oral supplements; Avenova Lubricating Eye Drops for instant relief; NovaWipes by Avenova; Avenova WarmEye Compress to soothe the eyes; and the i-Chek by Avenova to monitor physical eyelid health.